MTOR and tuberous sclerosis: Recently, the mTOR inhibitors everolimus and sirolimus have been shown to exhibit efficacy for the treatment of several manifestations of TSC such as subependymal giant cell astrocytomas (SEGA), seizures, renal angiomyolipomas, lymphangioleiomyomatosis, and facial angiofibroma lesions in patient with TSC [21–24].